{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:51:56Z","timestamp":1781610716810,"version":"3.54.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","giejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastrointestinal Endoscopy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.gie.2025.11.024","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:27:51Z","timestamp":1763692071000},"page":"77-85.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of endoscopy after recent bevacizumab use in metastatic colorectal cancer"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6900-5473","authenticated-orcid":false,"given":"Aditya","family":"Sood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Kit","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gie.2025.11.024_bib1","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gie.2025.11.024_bib2","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gie.2025.11.024_bib3","series-title":"AVASTIN\u00ae (Bevacizumab) [package insert]","year":"2022"},{"key":"10.1016\/j.gie.2025.11.024_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.gie.2025.11.024_bib5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.gie.2025.11.024_bib6","first-page":"1345","article-title":"Risk of gastrointestinal perforation in patients with colorectal cancer receiving bevacizumab: a meta-analysis of twenty-seven randomized controlled trials","volume":"29","author":"Qi","year":"2014","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.gie.2025.11.024_bib7","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1245\/s10434-006-9337-9","article-title":"Gastrointestinal perforation due to bevacizumab in colorectal cancer","volume":"14","author":"Saif","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.gie.2025.11.024_bib8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.7326\/M19-0642","article-title":"Screening for colorectal cancer in average-risk adults: a guidance statement from the American College of Physicians","volume":"171","author":"Qaseem","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gie.2025.11.024_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ags3.12312","article-title":"Bevacizumab\u2013associated intestinal perforation and perioperative complications in patients receiving bevacizumab","volume":"4","author":"Klosterman","year":"2020","journal-title":"Ann Gastroenterol Surg"},{"key":"10.1016\/j.gie.2025.11.024_bib10","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/ajg.2016.234","article-title":"Post-colonoscopy complications: a systematic review, time trends, and meta-analysis of population-based studies","volume":"111","author":"Reumkens","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gie.2025.11.024_bib11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.gie.2011.07.025","article-title":"Complications of colonoscopy","volume":"74","author":"Fisher","year":"2011","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gie.2025.11.024_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.gie.2025.11.024_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.71079\/ASIDE.IM.03222516","article-title":"TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research","volume":"1","author":"Nassar","year":"2025","journal-title":"ASIDE Int Med"},{"key":"10.1016\/j.gie.2025.11.024_bib14","first-page":"809","article-title":"A review on bevacizumab and wound healing: the process and evidence","volume":"13","author":"Gordon","year":"2020","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.gie.2025.11.024_bib15","first-page":"835","article-title":"Adverse events associated with EMR and ESD for the treatment of superficial esophageal neoplasia","volume":"81","author":"Chandrasekhara","year":"2015","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gie.2025.11.024_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176899","article-title":"Safety of endoscopy in cancer patients on antiangiogenic agents: a retrospective multicenter outcomes study","volume":"12","author":"Kachaamy","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.gie.2025.11.024_bib17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4253\/wjge.v14.i7.416","article-title":"Safety of endoscopy in patients undergoing treatments with antiangiogenic agents: a 5-year retrospective review","volume":"14","author":"Azam","year":"2022","journal-title":"World J Gastrointest Endosc"},{"key":"10.1016\/j.gie.2025.11.024_bib18","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1007\/s00464-020-07738-7","article-title":"Bevacizumab does not increase risk of perforation in patients undergoing percutaneous endoscopic gastrostomy or jejunostomy placement","volume":"35","author":"Dibba","year":"2021","journal-title":"Surg Endosc"}],"container-title":["Gastrointestinal Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016510725022011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016510725022011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:01:36Z","timestamp":1781607696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016510725022011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0016510725022011"],"URL":"https:\/\/doi.org\/10.1016\/j.gie.2025.11.024","relation":{},"ISSN":["0016-5107"],"issn-type":[{"value":"0016-5107","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of endoscopy after recent bevacizumab use in metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Gastrointestinal Endoscopy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gie.2025.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Society for Gastrointestinal Endoscopy","name":"copyright","label":"Copyright"}]}}